פאדסב 20 מג
astellas pharma international b.v., israel - enfortumab vedotin - אבקה להכנת תמיסה מרוכזת לעירוי - enfortumab vedotin 20 mg/vial - enfortumab vedotin
פאדסב 30 מג
astellas pharma international b.v., israel - enfortumab vedotin - אבקה להכנת תמיסה מרוכזת לעירוי - enfortumab vedotin 30 mg/vial - enfortumab vedotin
בימטופרוטס אס.קיי.
k.s.kim international (sk- pharma) ltd., israel - bimatoprost - תמיסה לעין - bimatoprost 0.3 mg / 1 ml - bimatoprost
טרבופרוסט אס.קיי.
k.s.kim international (sk- pharma) ltd., israel - travoprost - תמיסה לעין - travoprost 0.04 mg/ml - travoprost
דורזולאמיד אס.קיי.
k.s.kim international (sk- pharma) ltd., israel - dorzolamide as hydrochloride - טיפות עיניים - dorzolamide as hydrochloride 20 mg/ml - dorzolamide
חומצה כנודאוקסיכולית לדיאנט
mbi pharma ltd., israel - chenodeoxycholic acid - קפסולה קשיחה - chenodeoxycholic acid 250 mg - chenodeoxycholic acid
איקון
gem pharma ltd - hyaluronic acid as sodium - טיפות עיניים - hyaluronic acid as sodium 0.15 mg/ml - hyaluronic acid - hyaluronic acid - symptomatic treatment of dry eye syndrome.
סטאלבו 10025200 מג
inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.
סטאלבו 5012.5200 מג
inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.
מתוטרקסאט "אבווה" 10 מ"ג/מ"ל
pharmalogic ltd - methotrexate 10 mg/ml - solution for injection - methotrexate - antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. palliation of acute lymphocytic leukemia. in the treatment and prophylaxis of meningeal leukemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. in combination with other anticancer agents, methotrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. methotrexate is effective in the treatment of the advanced stages (iii and iv peter's staging system) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. psoriasis: because of the high risk attending its use, methotrexate is indicated only in the